VASCULAR SURGERY AS WE KNOW IT
HASN’T CHANGED IN OVER 60 YEARS

MEDICAL 21 IS CHANGING EVERYTHING.

Groundbreaking Development, Unparalleled Potential

Medical 21 is reshaping the future of cardiac bypass surgery by developing an artificial artery that will eliminate the need for blood vessel harvesting. This significant advancement can help reduce the systemic and painful challenges
that traditional Coronary Artery Bypass Graft surgery present.

The MAVERICS Graft System

Regenerative, Biocompatible, & Thrombo-Resistant

A Medical Technology Gamechanger

  • The MAVERICS graft is thin, flexible, and resilient enough to withstand the intense and very specific conditions the cardiovascular system requires.

  • The graft will be assimilated by the body allowing for perfusion of nutrients and cellular integration.

  • The nitinol scaffold adds arterial-like strength, flexibility, and biocompatibility.

CARDIOVASCULAR DISEASE IS A GLOBAL CONCERN

#1

18M

Cause of Death Worldwide

Annual Heart
Disease Deaths

2B

1M

Annual Bypass Surgeries Performed Worldwide

Adults At Risk
For Heart Disease

Coronary Artery Bypass Graft Surgery (CABG)

Physicians Need A Better Option for
Cardiac Revascularzation Procedures

Coronary Artery Bypass is a surgical procedure that restores blood flow in the heart. This is done by using veins harvested from other parts of a patient’s body to bypass a blocked artery.
It is the most common cardiac surgery performed worldwide, yet there hasn’t been an advancement to the procedure in 60 years.

  • Pain & Scarring at Harvesting Site

  • Longer Recovery Time

  • Risk Of Infection, Disfigurement, and Other Complications

  • Many Patients Are Ineligible: Diabetes, Varicose Veins, Amputees,

  • Long Procedures Mean Higher Costs and Reduced Availability

  • 25-30% Failure Rate in First Year, 50% in 5-10 Years

Vein Harvesting Poses Several Challenges:

MEDICAL 21 IS THE FUTURE

OF CORONARY ARTERY BYPASS SURGERY

  • No intrusive cuts or invasive removal of the patient’s veins.

  • Shorten procedure time and waiting lines by providing surgery to more patients with the same hospital resources.

  • Recovery is expected to take at least one day less in the hospital and dramatically improve length of full recovery.

  • Opportunity to provide surgery for patients with diabetes or amputations who were previously not eligible, as well as procedures that are strenuous on the veins such as rhino- surgery, pulmonary surgery, urinary surgery and dialysis.

Medical 21 Leadership

Meet The Team

MANNY VILLAFAÑA Ph.D.Sc
MASTER ENTREPRENEUR, FOUNDER OF MEDICAL 21

A HISTORY OF INNOVATION

Nationally recognized for over 50 years of entrepreneurship, medical device development , and 7 Initial Public Offerings, Medical 21 Founder and CEO Manny Villafaña has not only improved the quality of life for patients, but revolutionized the medical device industry time and time again.